Several types of cancer are under-represented in clinical trials

Current article ratings:
Patients / public:2 (1 votes)healthcare Prof:4 (1 votes)
Several types of cancer with high levels of disease received no clinical study on investment, the they of Australia need according to a study in the medical journal.

Dr. Rachel dear, an oncologist and doctoral student at the University of Sydney and co-author of scientific publications uses data from the Australian New Zealand clinical trials registry, the association between cancer clinical trial activity, to explore load by disease and sponsorship sources.

"Four of the five cancers that result in the largest burden had relatively few clinical studies (lung, colorectal, prostate, and pancreatic cancer) by disease," said Dr. dear.

"We have found that the number of attempts for each cancer not always the burden of the disease, by, that corresponded to cancer, and corresponding gaps in cancer research studies," said Dr. dear.

386 Interventional cancer open recruitment in Australia studies, breast cancer accounted for 62 studies. Still were only 24 studies on lung cancer, even though you responsible for the largest load performed by disease.

Dr. dear found that industry more controlled sponsorship for randomised studies, to examine the systemic therapy (drugs or biological agents) for patients with advanced tumors.

"Clinical trial registries are largely untapped resources describe the clinical research and future trial activity cause," she said.

In an accompanying editorial Professor Ian Olver of Cancer Council Australia said the study reflects the international situation, where investment in studies for certain types of cancer uncorrelated to the disease burden caused by this cancer is.

Data from clinical trial registries have many applications. Doctors and patients can trial options under certain conditions in the standard treatments have been exhausted or where is no effective treatment, said Professor Olver search.

"Data from clinical trial registries should be used, monitor the progress of such efforts to ensure that Australia has a robust clinical trial."

Source code
Medical Journal of Australia